Creative Medical Technology (NASDAQ:CELZ) Posts Quarterly Earnings Results

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings results on Friday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.16), FiscalAI reports.

Creative Medical Technology Stock Up 2.6%

Shares of NASDAQ CELZ traded up $0.02 during midday trading on Friday, hitting $0.62. 106,318 shares of the company’s stock were exchanged, compared to its average volume of 107,754. The firm has a market capitalization of $4.10 million, a PE ratio of -0.30 and a beta of 2.10. Creative Medical Technology has a 12 month low of $0.59 and a 12 month high of $4.72. The company’s 50 day moving average price is $0.87 and its 200 day moving average price is $1.54.

Analysts Set New Price Targets

Several research firms have issued reports on CELZ. Roth Capital reaffirmed a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Weiss Ratings downgraded shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. Finally, Wall Street Zen raised shares of Creative Medical Technology from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Creative Medical Technology has an average rating of “Hold”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.

The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.